CBER Director Peter Marks (Susan Walsh/Pool via AP Images)
September 5, 2024 02:52 PM EDT
Cell/Gene Tx
FDA+

CBER chief fore­casts bet­ter glob­al reg­u­la­to­ry con­ver­gence around cell and gene ther­a­pies

Zachary Brennan

Senior Editor

Pe­ter Marks, who’s re­spon­si­ble for the FDA’s over­sight of cell and gene ther­a­pies, ex­pects reg­u­la­tors around the world will be bet­ter at col­lab­o­rat­ing on gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times